U.S. Markets open in 6 hrs 20 mins

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. - ACRX

NEW YORK, Oct. 16, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether AcelRx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On October 12, 2017, AcelRx advised investors that the Company had received a complete response letter from the U.S. Food and Drug Administration ("FDA") regarding AcelRx's New Drug Application for DSUVIA for the treatment of moderate-to-severe acute pain.  The FDA requested the collection of additional data on "at least 50 patients to assess the safety of DSUVIA" and recommended certain changes to the Directions for Use to address use-related errors. 

On this news, the Company's shares fell $3.20 or 59.81%, to close at $2.15 on October 12, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

Robert S. Willoughby
Pomerantz LLP


View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-acelrx-pharmaceuticals-inc--acrx-300537424.html